News | July 27, 2021
Biocon Biologics partners Adagio to manufacture antibody for COVID-19
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
Oxygen Park is a concept where a two-layer layout is being used to plant oxygen releasing trees which releases oxygen for 24 hours
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Subscribe To Our Newsletter & Stay Updated
